Degradation of Condensate for Drug Discovery

CD BioSciences offers a variety of condensate-based drug discovery strategies to achieve repair condensatopathy, disrupt the normal function of condensates associated with disease, and prevent targets from acting by disabling them in their natural condensates or by separating them from their natural condensates. Here, we help you with drug development by degrading pathological condensates.

Introduction of Proteolysis-Targeting Chimera (PROTAC)

Proteolysis-targeting chimera (PROTAC) is a useful technique for targeted protein degradation. A bifunctional PROTAC molecule consisting of a ligand for the target protein and a covalently linked ligand for the E3 ubiquitin ligase is recruited together with the E3 ubiquitin ligase to trigger proteasomal degradation of the target protein by the ubiquitin-proteasome system. PROTAC complements nucleic acid-based knockout/knockdown technologies for targeted protein reduction and can mimic pharmacological protein inhibition. To date, PROTAC has emerged as a promising approach for targeted therapies for a variety of diseases, particularly cancer. Studies have shown that PROTAC or molecular gel strategies can effectively remove specific proteins from condensates through degradation.

Fig. 1. Principles and development of PROTAC. (Li X, et al, 2020)

Our Solutions

CD BioSciences, a leading company specializing in drug discovery and development, recognizes the importance of condensate biology in advancing novel therapeutics. Using our expertise in biological research and innovative technologies, we offer innovative solutions for degradting condensates as a novel approach to drug discovery.

Our solutions involve the use of small molecule degraders (including molecular gels and heterobifunctional degraders, such as PROTAC) that specifically interact with components of abnormal condensates, leading to their dissolution or preventing their formation. We

• Our experts have identified and characterized a series of dissolvers condensate-modifying therapeutics with different mechanisms of action that can precisely target different types of condensates.
• We offer several PROTAC design strategies for neurodegenerative targets, including TDP43, α-Synuclein, Tau, and Huntington's protein.
• Our services also offer potential solutions for overcoming drug resistance in breast cancer and other malignancies.

Advantages of Our Solutions for Degradating Condensates

• Precision and selectivity in condensate targeting. Through meticulous characterization and screening, we ensure that small molecule degraders interact specifically with aberrant condensate components without affecting normal condensate kinetics necessary for cellular function.
• A multi-modal approach for maximizing condensate degradation efficiency. By combining dissolvers condensate-modifying therapeutics with other therapeutic modalities, such as small molecules, peptides, or gene therapy, we can achieve synergistic effects and enhance therapeutic efficacy. This integrated strategy broadens the range of diseases that can be targeted by our degraded condensate solutions and offers hope to patients suffering from different conditions.

In the era of precision medicine and targeted therapies, CD BioSciences is at the forefront of condensate biology and drug discovery. We offer innovative solutions to degrade abnormal condensates associated with disease pathology. Our solutions have the potential to revolutionize therapeutic areas such as neurodegenerative diseases, cancer drug resistance, etc. If you are interested in our solutions, please contact us now to seize new drug development opportunities.